Literature DB >> 8819231

Ras and myelodysplasia: lessons from the last decade.

J Parker1, G J Mufti.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8819231

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  6 in total

Review 1.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Antiangiogenic therapy in myelodysplastic syndromes: is there a role?

Authors:  Stephen T Oh; Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2008-01       Impact factor: 3.952

Review 3.  Important features of myelodysplastic syndrome.

Authors:  Wolf K Hofmann; H Phillip Koeffler
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

4.  Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms.

Authors:  Agnes Fütterer; Miguel R Campanero; Esther Leonardo; Luis M Criado; Juana M Flores; Jesús M Hernández; Jesús F San Miguel; Carlos Martínez-A
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

5.  Mutant N-RAS induces erythroid lineage dysplasia in human CD34+ cells.

Authors:  R L Darley; T G Hoy; P Baines; R A Padua; A K Burnett
Journal:  J Exp Med       Date:  1997-04-07       Impact factor: 14.307

6.  K-ras/PI3K-Akt signaling is essential for zebrafish hematopoiesis and angiogenesis.

Authors:  Lihui Liu; Shizhen Zhu; Zhiyuan Gong; Boon Chuan Low
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.